Quanterix®
The Science of Precision Health



Q4 2018 Earnings Call • March 7, 2019

Forward-Looking Statements

This presentation contains “forward-looking” statements that are based on our beliefs and assumptions and on information available to us as of the date of this presentation. Forward-looking statements include all statements that are not historical facts. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties, assumptions and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. The risks and uncertainties that we face are described in our most recent filings with the Securities and Exchange Commission. Except as required by law, we assume no obligation to update these forward-looking statements, even if new information becomes available in the future.

This presentation will also include certain financial measures that were not prepared in accordance with U.S. GAAP. The information required by the SEC pursuant to Regulation G, including reconciliation of the non-GAAP financial measures to the most directly comparable GAAP financial measures, can be found in our earnings release issued previously today, which is on our website.

Today's Agenda

I. Strategic and Financial Progress – Kevin Hrusovsky – Chairman, CEO

   i. Q4 and FY 2018 Highlights

   ii. 2018 / 2019 Goals & Priorities

   iii. Transforming Medicine: Neurology Momentum Update

II. Financial Report – Joe Driscoll – CFO

III. Summary of QTRX Opportunity - Kevin Hrusovsky

IV. Q&A

Massive Market Opportunity, Disruptive Technology and a Track Record for Execution

Quanterix
The Science of Precision Health

Exquisite Biomarker Sensitivity



900x sensitivity increase

Superb Execution

- Aushon acquisition
- Regained IVD rights
- Attracting Top Talent
- Two FDA Nf-L sessions
- Launch SR-X, SP-X, CorPlex
- EU Powering Precision Health Summit

Total QTRX Revenue Growth



Research
Market: $1B → $8B

Now: Rev 0 - $38M; Neuro and Onco

300%
increase in probability of drug approval

Starting 2020: LDT – IVD - DTC

Diagnostics
Market: $30B+

FY2018 Growth is Accelerating Across All Segments

- Revenue $10.9M, +65% vs. PY Q4
- High margin mix accelerating, Consumables growth +67%; GM 48.2%, +450bp

65% Growth

Q4'18 Revenue



- Revenue $37.6M, +65%, +60% excl 1 time
- GM +410bp, +259bp adjusting 1 time
- Consumable pull-through grew from 35% of list price in Q1 to 41% in Q4; FY 40%
- Instrument growth accelerated in 2H after 3 years of flat growth

60% Growth

FY'18 Revenue



Scientific Research is Driving Brand Awareness, Performance and Utilization

Quanterix
The Science of Precision Health

PUBLICATIONS



MARKERS



ACCELERATOR



Number of drug trial projects completed

INSTRUMENTS*



Revenue Growth %

*Instrument segmentation estimated based on consumables sold

CONSUMABLES



Consumable growth

FY2018 Growth Stratification



Geography

	Growth
NA	+64%
Europe	+69%
Asia	+54%

Customer

	Growth
Pharma/Biotech CRO	+63%
Academia	+69%

Diseases

	Growth
Neurology	+73%
Oncology	+110%
Cardiology	+242%
ID	+101%

} 92%

2018 Investor Targets and Catalysts

Quanterix
The Science of Precision Health

FINANCIALS

METRIC	STATUS
Revenue: 40% growth	+65%
Instrument +20%	>46%
Annual Utilization: 33% List Price	40% List
GM: +300bps.	+410bps

NEW PRODUCTS

METRIC	STATUS
SR-X 50	>70 booked
SP-X 6+ plex prototype	Q4 test bed 10 plex
25 new assays	69+
CLIA Lab for Pharma	Aushon Acquired

COMMERCIAL

Add 20 Commercial HC	25 + INVESTORS, 60 all functions
Pubs 275+	409
100% TOP PHARMA	10/10, 19/20 top; ~800+ trials

STRATEGY

Restore Diagnostics rights	**ACHIEVED**
PPH sponsorship	PPH Europe Success
FDA Advancement	Two Meetings; ODES
Market Expansion	R: $1B→$8B; D: $30B

Overachieved | Achieving | Marginal Risk | High Risk

2019 Targets & Growth Catalysts

LSR Neurology

Continue high double digit growth w/ high utilization

Only <10% penetrated

- Expand SR-X / HD1 Menu Add 25 Assays
- Launch HD-X 4Q
- Scale globally, IT and facilities. Add 40 HC / ½ commercial.

LSR Oncology

3x larger than Neuro w/ minimal penetration today

- Launch SP-X 1H
- Launch CorPlex Assays – 10 plex

Enter diagnostics:

1. 50 Drug Trials (neuro/onco)
2. LDT partner (explore direct)
3. Explore IVD partnerships
4. Sponsor PPH

Financials:

Long-term growth: 40%

Utilization: Drive incremental utilization across all platforms

Gross Margin: 300 bps

Instrument: 25% growth

- **100x more sensitivity by 2021 YE**
- Lead next frontier of medicine; Protein Translational Modifications

Simoa: Technology and Instrumentation

Quanterix
The Science of Precision Health

Sensitivity & Assay Precision

simoa

3rd Generation

Quanterix



HD-1
(2014)



SR-X
(2018)

HD-X
(2H 19)

Quanterix

SP-X
(1H 19)

4th Generation

100x Sensitivity
Target by 2021

Luminex
1st Generation

MSD
2nd Generation

Fluorescence — Chemiluminescence

Beads — Planar

Competitive Landscape

Quanterix
The Science of Precision Health

	Quanterix	Luminex	MilliporeSigma Singulex	MSD	proteinsimple
Technology	Bead-Based Simoa	Planar SP-X Simoa	Bead-based Immunoassay	Erenna Immunoassay	Electrochemi-luminescence	ELLA
Sensitivity						
Dynamic Range						
Automation & Ease of Use						
Precision						
Multiplexing						
Menu						
Cost						

Transforming Medicine with Digital Biomarkers

Quanterix
The Science of Precision Health

Today: Invasive and Late





Tomorrow: Non invasive and Early



Simoa Neurology Publications – Catalyzing Disruption

Quanterix
...e of Precision Health



Biogen
SANOFI
Pfizer
Lilly
Genentech
A Member of the Roche Group
NOVARTIS

Spinal taps

- Alzheimer's Disease
- TBI/concussion
- Multiple sclerosis
- Parkinsons, ALS, FTD, etc

2012
2013
2014
(6)
2015
(13)
2016
(41)
2017
(78)
2018
(176)
2019

Neurology 08 Feb 2019
NFL clinically validated for monitoring MS & treatment response in 2 Phase III trials.

nature medicine 31 Jan 2019
NFL predicts clinical progression in pre-symptomatic Alzheimer's disease 16 years before onset.

HEAD HEALTH CHALLENGE NFL
2x winner

GOOD MORNING AMERICA
Bloomberg

BREAKING NEWS
NEW BLOOD TEST CAN PREDICT ALZHEIMER'S DISEASE LIVE CNN

Simoa Neurology Publications – Catalyzing Disruption



Neurology Momentum Fueling Growth and Future Strategy



- Strongest **growth in neurology** RUO franchise with **accelerating publications** 2018
- **Nf-L, amyloid beta, tau**, and other markers showing tremendous **potential for key clinical applications** in top peer-reviewed pubs
- Strong network of **world-leading KOLs**
- Inbound **FDA interest** (Nf-L); recent **breakthrough device exemption** for AB40/42 mass spec test for Alzheimer's
- **Media, patient advocacy, and public attention** to promise of blood-based neurology tests (CNN, Forbes, Bloomberg, Washington Post, GMA, etc.
- **Deep adoption** by leading academic and pharma

Neurofilament Light in Research Studies for MS and Other Neurological Conditions Accelerating Rapidly

Quanterix
The Science of Precision Health

RESEARCH PUBLICATIONS ON NFL



Abstract: Neurology 2019: Blood NfL levels are associated with clinical and MRI-related measures of disease activity and neuroaxonal damage and have prognostic value. Our results support the utility of blood NfL as an easily accessible biomarker of disease evolution and treatment response.

Editorial
Neurofilament light chain: An important step toward a disease biomarker in multiple sclerosis
Page 451

Source: Health Advances analysis, PubMed.

>$22B Spent Annually on MS Drugs with 62 Active Clinical Trials

Quanterix
The Science of Precision Health

MULTIPLE SCLEROSIS* THERAPIES IN DEVELOPMENT

N=62 Drug Trials
Estimate 10 already using sNF-L



*Excludes non-industry sponsored trials, active-not yet recruiting, enrolling by invitation, or unknown status trials
Source: Health Advances commissioned research, 2018

MULTIPLE SCLEROSIS CATEGORY MARKET SHARE BY & SALES



OTHERS	
Abby	0.3%

NOVARTIS
Genentech
A Member of the Roche Group
genzyme
Biogen
Roche
SANOFI

Simoa NfL Multicenter Analytical Validation - 17 sites across Europe and North America

Quanterix
The Science of Precision Health

	Location	Investigator	Study Site
1	Amsterdam	Dr. Charlotte	Neurochemistry Laboratory, Amsterdam University
2	Barcelona	Dr. Manuel	Laboratori de Neuroinmunologia Clinica Centre
3	Basel	Prof Jens Kuhle, Dr. Zuzanna	Department Biomedicine, Univ Hospital Basel, Switzerland
4	Dresden	Dr. Katja Akgün Dr. Ziemssen, Tjalf	Neuroimmunological lab, Center of Clinical Neuroscience, Dresden, Germany
5	Gothenburg	Prof. Kaj Blennow Prof. Henrik	Clinical Neurochemistry Lab, Mölndal Hospital, Mölndal, Sweden
6	Göttingen	Prof. Wolfgang Dr. Niels Kruse	Institut für Neuropathologie, Universitätsmedizin Göttingen, Germany
7	London	Dr. Lucia Bianchi Prof. Gavin	Dept of Neuroscience & Trauma Blizard Institute Queen Mary Univ of London, UK
8	London	Dr. Amanda Prof. Henrik	The DRI Fluid Biomarker Laboratory at University College London, United Kingdom
9	Mainz	Prof. Stefan Bittner	Klinik für Neurologie, Universitätsmedizin Mainz,
10	Milan	Dr. Comi Giancarlo Prof.Roberto Furlan	Clinical Neuroimmunology Unit - Institute of Experimental Neurology, MIlan, Italy
11	Montpellier	Prof. Markus Otto Dr. Patrick Oeckl	Hôpital St Eloi, Montpellier, France
12	Ulm	Prof. Markus Otto Dr. Patrick Oeckl	University of Ulm, Ulm, Germany
13	Bethesda	Dr. Ruturaj Dr. Bibi Bielekova	National Institutes of Health, Bethesda, MD
14	Ottawa	Dr. Simon Thebault Dr. Freedman, Mark Dr. Booth, Ronald	MS Clinical Ottawa Hospital University of Ottawa, Ottawa ON Canada
15	Philadelphia	Dr. Marcus Handy Dr. Amit Bar-Or	Perelman School of Medicine, University of Pennsylvania, Department of Neurology, Philadelphia,
16	Lexington	Kevin Hrusovsky Dr. David Wilson	Quanterix Corp, Lexington MA
17	Framingham	Dr. Matthew Dr. Martin Kramer	Sanofi Genzyme, Framingham MA

Simoa: NfL Multicenter Validation – Assay Consistency

Quanterix
The Science of Precision Health

Multiple Sclerosis Sample Results – all sites



Assay reproducibility – all sites



Emerging Clinical Biomarker: Neurofilament Light (NfL)

Quanterix
The Science of Precision Health

NFL PUBLICATIONS



STUDIES CONFIRM NFL CLINICAL UTILITY:

- Disease activity monitoring
- Drug efficacy monitoring
- Relapse/severity prognostic

WW DISEASE INCIDENCE (MILLIONS)



MULTIPLE SCLEROSIS:

- Avg. age of onset: 34 yrs; avg. life expectancy after onset: 30 yrs
- Standard of care: MRI 1-2X/yr
- NfL as MRI replacement: 3.5M tests/yr

Majority of published data obtained with Simoa NfL

Clinical Vaildation of NfL for MS is a Key Beachhead

Digital Biomarkers Disruption Paradigm: Alzheimer's Disease Opportunity

Quanterix
The Science of Precision Health

Today

Alzheimer's disease not diagnosed until symptoms

Imaging expensive and often not covered

Therapies for later stage disease have limited effectiveness

Tomorrow

Detect or screen in annual blood test

CNN

Follow on Image or blood test to diagnose

Therapy delivered sooner with less dosing / toxicity. Blood test monitors progression

QTRX Taking Aim at Alzheimer's Disease with Simple Blood Test

Quanterix
The Science of Precision Health



2018



Plasma NfL exhibits high diagnostic accuracy for Alzheimer's Disease (AUC 0.87)

2018



Plasma Aβ42/Aβ40 ratio exhibits high diagnostic accuracy for **amyloid positive patients (AUC 0.95)**



2019



Serum NfL predicts clinical progression in pre-symptomatic Alzheimer's disease **16 years before onset.**

NEW BLOOD TEST CAN PREDICT ALZHEIMER'S DISEASE

LIVE CNN

FOX NEWS

$1,400M

Every **65 SECONDS** SOMEONE IN THE UNITED STATES DEVELOPS THE DISEASE.
Every **3 SECONDS** SOMEONE IN THE WORLD DEVELOPS THE DISEASE

5.8 MILLION AMERICANS ARE LIVING WITH ALZHEIMER'S. BY 2050, THIS NUMBER IS PROJECTED TO RISE TO NEARLY 14 MILLION.

44 MILLION PEOPLE ARE LIVING WITH ALZHEIMER'S WORLDWIDE

LUND UNIVERSITY

UNIVERSITY OF GOTHENBURG

ADNI
Alzheimer's Disease Neuroimaging Initiative

MERCK

AstraZeneca

NOVARTIS

janssen

Amsterdam UMC
Universitair Medische Centra

Biogen **Aducanumab**

Genentech
A Member of the Roche Group

Lilly

GRIFOLS

Allergan

DZNE
German Center for Neurodegenerative Diseases within the Helmholtz Association

Blood Test May Detect Alzheimer's In Patients 16 Years Before Symptoms Appear

Quanterix
The Science of Precision Health

CNN Health » Food | Fitness | Wellness | Parenting | Live Longer — Live TV — U.S. Edition +

Blood test could detect Alzheimer's up to 16 years before symptoms begin, study says

By Nina Avramova, CNN
Updated 2:45 PM ET, Tue January 22, 2019



How to prevent Alzheimer's disease 03:33

More from CNN


Passengers spend 14 hours stuck on grounded flight


UFC's Allen Crowder Has 'No Hard Feelings' Toward Greg Hardy...

(CNN) — A simple blood test could predict if a patient will develop Alzheimer's disease up to 16 years before symptoms begin, a new study finds.

By measuring changes in the levels of a protein in the blood, called neurofilament light chain (NfL), researchers believe any rise in levels of the protein could be an early sign of the disease, according to the study published Monday in the journal Nature Medicine.

NfL is a "marker in the blood which gives an indication of nerve cell loss in the brain," explained lead researcher Mathias Jucker, professor of cell biology of neurological diseases at the German Center for Neurodegenerative Diseases. "The more neurofilament you have in the blood, the more brain damage you have," he said.



nature medicine — LETTERS
https://doi.org/10.1038/s41591-018-0304-3

Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease

Oliver Preische[1,2,21], Stephanie A. Schultz[3,21], Anja Apel[1,2,21], Jens Kuhle[4], Stephan A. Kaeser[1,2], Christian Barro[4], Susanne Gräber[1], Elke Kuder-Buletta[1], Christian LaFougere[1], Christoph Laske[1,2], Jonathan Vöglein[5,6], Johannes Levin[5,6], Colin L. Masters[7], Ralph Martins[8,9], Peter R. Schofield[10,11], Martin N. Rossor[12], Neill R. Graff-Radford[13], Stephen Salloway[14], Bernardino Ghetti[15], John M. Ringman[16], James M. Noble[17], Jasmeer Chhatwal[18], Alison M. Goate[19], Tammie L. S. Benzinger[3], John C. Morris[3], Randall J. Bateman[3], Guoqiao Wang[3], Anne M. Fagan[3], Eric M. McDade[3], Brian A. Gordon[3], Mathias Jucker[1,2*] and Dominantly Inherited Alzheimer Network[20]

Neurofilament light chain (NfL) is a promising fluid biomarker of disease progression for various cerebral proteopathies. Here we leverage the unique characteristics of the Dominantly Inherited Alzheimer Network and ultrasensitive immunoassay technology to demonstrate that NfL levels in the cerebrospinal fluid ($n = 187$) and serum ($n = 405$) are correlated with one another and are elevated at the presymptomatic stages of familial Alzheimer's disease. Longitudinal, within-person analysis of serum NfL dynamics ($n = 196$) confirmed this elevation and further revealed that the rate of change of serum NfL could discriminate mutation carriers from non-mutation carriers almost a decade earlier than cross-sectional absolute NfL levels (that is, 16.2 versus 6.8 years before the estimated symptom onset). Serum NfL rate of change peaked in participants converting from the presymptomatic to the symptomatic stage and was associated with cortical thinning assessed by magnetic resonance imaging, but less so with amyloid-β deposition or glucose metabolism (assessed by positron emission tomography). Serum NfL was predictive for both the rate of cortical thinning and cognitive changes assessed by the Mini-Mental State Examination and Logical Memory test. Thus, NfL dynamics in serum predict disease progression and brain neurodegeneration at the early presymptomatic stages of familial Alzheimer's disease, which supports its potential utility as a clinically useful biomarker.

In most neurodegenerative diseases, brain changes manifest many years before clinical symptoms become apparent. In Alzheimer's disease, presymptomatic changes in the brain include cortical thinning and neuropathological depositions containing amyloid-β and tau. These pathological changes can be assessed by magnetic resonance imaging (MRI), positron-emission tomography (PET), and measurement of amyloid-β and tau protein levels in the cerebrospinal fluid (CSF)[1–4]. However, CSF collection is invasive and imaging modalities are expensive; therefore, they are not well suited to routine clinical practice. Blood biomarkers for the presymptomatic phase of Alzheimer's disease are largely lacking, although recent progress in the analysis of amyloid-β, tau, and neurofilament light chain (NfL) in the blood have been reported[5–10].

NfL is a component of the axonal cytoskeleton and is primarily expressed in large-caliber myelinated axons[11,12]. Changes of NfL in bodily fluids have been linked to brain damage and brain atrophy in mouse models and multiple neurological disorders including

[1]German Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany. [2]Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, and Department of Psychiatry and Psychotherapy, University of Tübingen, Tübingen, Germany. [3]Department of Neurology, Department of Radiology, and Division of Biostatistics, Washington University School of Medicine, St. Louis, MO, USA. [4]Neurologic Clinic and Policlinic, Departments of Medicine, Biomedicine and Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland. [5]German Center for Neurodegenerative University, Providence, RI, USA. [15]Indiana Alzheimer Disease Center and Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USA. [16]Department of Neurology, Keck School of Medicine at USC, Los Angeles, CA, USA. [17]Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Department of Neurology, Columbia University Medical Center, New York, NY, USA. [18]Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. [19]Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, NY, USA. [20]A full list of members and affiliations appears at the end of the paper. [21]These authors contributed equally: Oliver Preische, Stephanie A. Schultz, Anja Apel. *e-mail: mathias.jucker@uni-tuebingen.de

Fig. 3 | Rate of change per year in serum NfL in mutation carriers mirrors rate of change in cortical thinning. a, Relationship between estimated annual rate of change in serum NfL and estimated annual rate of change in precuneus cortical thickness for non-carriers, presymptomatic (Presym) mutation carriers, and symptomatic (Sym) mutation carriers (including converters to the symptomatic phase, see Fig. 2c). Results from LMEMs revealed

Simoa: Potentially Superior to Mass Spectrometry for Plasma Amyloidosis Detection

Quanterix
The Science of Precision Health

ROC analysis on similarly powered preliminary studies

Mass spectrometry[1]

AUC = 0.89



Simoa[2]

AUC = 0.95



1. Ovod et al. Alzheimers Dement.August ; 13(8): 841–849 (2017)

2. Thijssen et al, AAIC 2018

Simoa: In the News

PPH 2018 - Amsterdam

ABC – Feb 2019

Bloomberg Radio Feb 2019

nature medicine

CNN

31 Jan 2019

NfL predicts clinical progression in pre-symptomatic Alzheimer's disease 16 years before onset

MDLinx

February 2019

Comment

Could MS be diagnosed with a simple blood test?

Poised to Disrupt Healthcare and Create Significant Value

Quanterix
The Science of Precision Health

market

Quanterix

execution

		Differentiator	Value
1	Category-defining; Unrivaled Sensitivity / Technology	Best in Class	Disrupt
2	Methodical market penetration strategy to reward investors	$3B to $38B	New Answers
3	DNA – RNA - Protein; Better linked to Disease / Health		Holy Grail
4	**Validation**: 19/20 top pharma, PPH, 800+ trials	400+ pubs All Areas	Proven
5	Growth & Value; Razor – razor blade, $150M invested	Product Launches	Rapid Growth
6	Low Risk / Solid Return + Uber Return Prospect		Retail
7	Track Record for Commercializing Disruption		Lynchpin